Head to Head Analysis: JATT Acquisition (NYSE:JATT) vs. Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ:EDIT) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Profitability

This table compares Editas Medicine and JATT Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-340.96%	-80.13%	-50.99%
JATT Acquisition	N/A	-49.58%	2.84%

Insider and Institutional Ownership

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 1.9% of Editas Medicine shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Editas Medicine and JATT Acquisition”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$61.76 million	1.94	-$153.22 million	($2.56)	-0.57
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A

JATT Acquisition has lower revenue, but higher earnings than Editas Medicine.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Editas Medicine and JATT Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	2	9	3	0	2.07
JATT Acquisition	0	0	0	0	0.00

Editas Medicine currently has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Given Editas Medicine’s stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than JATT Acquisition.

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.